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Abstract. 
 
The chemokine receptor CCR5 is a cofactor for
the entry of R5 tropic strains of human immunodeﬁciency
viruses (HIV)-1 and -2 and simian immunodeﬁciency vi-
 
rus. Cells susceptible to infection by these viruses can
 
be protected by treatment with the CCR5 ligands regu-
lated on activation, normal T cell expressed and secreted
 
(RANTES), MIP-1
 
a
 
, and MIP-1
 
b
 
. A major component of
the mechanism through which chemokines protect cells
from HIV infection is by inducing endocytosis of the
 
chemokine receptor. Aminooxypentane (AOP)-RANTES,
 
an NH
 
2
 
-terminal modiﬁed form of RANTES, is a potent
inhibitor of infection by R5 HIV strains. AOP-RANTES
efﬁciently downmodulates the cell surface expression of
CCR5 and, in contrast with RANTES, appears to prevent
recycling of CCR5 to the cell surface. Here, we investigate
the cellular basis of this effect.
 
Using CHO cells expressing human CCR5, we show
that both RANTES and AOP-RANTES induce rapid in-
ternalization of CCR5. In the absence of ligand, CCR5
shows constitutive turnover with a half-time of 6–9 h.
Addition of RANTES or AOP-RANTES has little effect
on the rate of CCR5 turnover. Immunoﬂuorescence and
immunoelectron microscopy show that most of the
CCR5 internalized after RANTES or AOP-RANTES
treatment accumulates in small membrane-bound vesi-
cles and tubules clustered in the perinuclear region of
the cell. Colocalization with transferrin receptors in the
same clusters of vesicles indicates that CCR5 accumu-
lates in recycling endosomes. After the removal of
RANTES, internalized CCR5 recycles to the cell surface
and is sensitive to further rounds of RANTES-induced
endocytosis. In contrast, after the removal of AOP-
RANTES, most CCR5 remains intracellular. We show
that these CCR5 molecules do recycle to the cell sur-
face, with kinetics equivalent to those of receptors in
RANTES-treated cells. However, these recycled CCR5
molecules are rapidly reinternalized. Our results indicate
that AOP-RANTES–induced changes in CCR5 alter the
steady-state distribution of the receptor and provide the
ﬁrst evidence for G protein–coupled receptor trafﬁcking
through the recycling endosome compartment.
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Introduction
 
Chemokine receptors are members of the large family of
seven transmembrane domain G protein–coupled recep-
 
tors (GPCR)
 
1
 
 that function in immune and inflammatory
responses by regulating the activation and directed migra-
tion of leukocytes (Pelchen-Matthews et al., 1999; Murphy
et al., 2000). These receptors have also been implicated in
hematopoiesis, development, angiogenesis, and, recently,
in the entry and infection of two groups of animal viruses,
the primate immunodeficiency viruses (HIV-1 and -2, and
simian immunodeficiency virus) and the rabbit poxvirus
responsible for myxomatosis (Berger et al., 1999; Lalani et
al., 1999; Murphy et al., 2000). Although various chemo-
kine receptors have been shown to facilitate the entry of
HIV-1 and its relatives in vitro, the receptors that have
been most strongly implicated in disease are the CC
chemokine receptor 5 (CCR5) and CXCR4 (Berger et al.,
1999; Pelchen-Matthews et al., 1999; Murphy et al., 2000).
 
CCR5 is a receptor for the CC chemokines regulated
on activation, normal T cell expressed and secreted
 
(RANTES), MIP-1
 
a
 
, MIP-1
 
b
 
, and MCP-3 and is ex-
pressed on peripheral blood-derived dendritic cells, sub-
 
sets of Th1 lymphocytes, and CD34
 
1
 
 haematopoietic stem
 
J
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cells (Murphy et al., 2000). In contrast, CXCR4 binds
uniquely the CXC chemokine stromal cell-derived factor
1, and it is expressed on most haematopoietic cells, includ-
ing neutrophils, monocytes, T and B lymphocytes, den-
dritic cells, and macrophages, as well as vascular endothe-
lial cells, neurons, and glia (Murphy et al., 2000). Current
evidence suggests that, together with CD4, CCR5 is im-
portant for the transmission of CCR5 tropic strains of HIV
(R5 viruses) and the establishment of infection. CXCR4
tropic viruses (X4 viruses) can emerge in infected individ-
uals during the course of infection or passage of virus
through T cell lines in culture (Berger et al., 1999).
The initial indication that chemokine receptors have a
role in HIV infection came from the finding that the CC
chemokines RANTES, MIP-1
 
a
 
, and MIP-1
 
b
 
 can inhibit
HIV infection in vitro
 
 
 
(Cocchi et al., 1995)
 
. 
 
Subsequently,
stromal cell-derived factor 1 was also shown to inhibit in-
fection by X4 viruses (Bleul et al., 1996; Oberlin et al.,
1996). Two models have been proposed for the mechanism
through which chemokines inhibit HIV entry (Wells et al.,
1996). One proposal is that interaction of the chemokine
with its receptor masks a binding site(s) on the chemokine
receptor that is involved in docking of the viral envelope
protein. The alternative is that the chemokine induces ac-
tivation and internalization of the receptor so that it is no
longer available on the cell surface for virus binding. Evi-
dence has accumulated that certain receptor antagonists
can block the viral envelope protein-binding sites on the
receptor without inducing receptor endocytosis (Aren-
zana-Seisdedos et al., 1996; Doranz et al., 1997; Klasse et
al., 1999). However, studies with native chemokines indi-
cate that a major component of the mechanism through
which these molecules inhibit HIV entry is by inducing en-
docytosis of the chemokine receptor (Amara et al., 1997;
Signoret et al., 1997). Subsequently, a modified form of
the CC chemokine RANTES, in which an aminooxypen-
tane group (AOP) is coupled to the NH
 
2
 
 terminus of the
protein, was shown to be a particularly effective inhibitor
of R5 tropic HIV strains (Simmons et al., 1997). Signifi-
cantly, this activity appeared to correlate with the ability
of AOP-RANTES to irreversibly downmodulate CCR5
(Mack et al., 1998). Initial studies of the fate of CCR5 in
cells treated with RANTES or AOP-RANTES indicate
that both ligands induce CCR5 endocytosis through clath-
rin-coated vesicles (Amara et al., 1997; Aramori et al.,
1997; Mack et al., 1998; Signoret et al., 1998), but only in
RANTES-treated cells is CCR5 recycled to the cell sur-
face after ligand removal (Mack et al., 1998).
Here, we investigated the cellular mechanisms of ligand-
induced CCR5 trafficking. We find that both RANTES
and AOP-RANTES induce endocytosis of CCR5 with
similar kinetics. With both ligands, internalized receptors
are delivered to endosomal vesicles with properties similar
to those described for recycling endosomes. After removal
of RANTES, CCR5 reaccumulates on the cell surface.
In contrast, on AOP-RANTES–treated cells, CCR5 ap-
peared to remain inside the cell. However, antibody feed-
ing experiments indicated that this CCR5 was able to recy-
cle to the cell surface, and that the recycled receptor was
rapidly reinternalized. The results suggest that AOP-
RANTES is able to modify CCR5 such that the receptor
continues to be recognized by the endocytosis machinery
and is unable to reaccumulate on the cell surface.
 
Materials and Methods
 
Reagents
 
Tissue culture reagents and Nunc tissue culture plastic were from Life
Technologies. Chemicals were from Sigma-Aldrich, unless indicated. Ra-
dioactive reagents were from Amersham Pharmacia Biotech. Recombinant
RANTES was prepared as described previously (Proudfoot et al., 1996).
AOP-RANTES was produced as described previously (Simmons et al.,
1997) and was provided by Robin E. Offord (Centre Medical Universitaire,
Geneva, Switzerland). 
 
125
 
I-RANTES and 
 
125
 
I–AOP-RANTES (specific ac-
tivity 2,000 Ci/mmol) were prepared by enzymatic iodination with sodium
[
 
125
 
I]iodide, hydrogen peroxide, and lactoperoxidase and then purified by
high performance liquid chromatography (Nycomed Amersham plc).
 
Antibodies
 
The anti-CCR5 murine mAb MC-5 (IgG2a) was generated as described
previously (Segerer et al., 1999), and its specificity was determined on
CHO cells stably transfected with human CCR1-5 or CXCR4. Binding was
only detected on cells expressing CCR5. The antibody did not react with
freshly isolated peripheral blood mononuclear cells, or with cultured
monocytes from donors homozygous for the CCR5 
 
D
 
32 mutation (Segerer
et al., 1999). The MC-5 epitope has been mapped to the NH
 
2
 
-terminal do-
main of the receptor, with amino acids 2–4 being crucial for binding. Puri-
fied MC-5 was radioiodinated using 
 
125
 
I-Bolton and Hunter reagent (Am-
ersham Pharmacia Biotech), as described previously (Signoret et al., 1997).
The anti–hamster lysosomal glycoprotein mAbs to Lgp-B (Lgp-120)
UH3c and 3E9 (both IgG1), 1B3-13 (IgG2a), and hamster CD63 (eh1c9b,
IgG2a) were provided by Dr. Bruce Granger (Montana State University,
Bozeman, MO). The anti–lysobisphosphatidic acid (LBPA) mAb 6C4
(IgG1) (Kobayashi et al., 1998) was provided by Dr. Jean Gruenberg
(Universite de Geneve, Geneva, Switzerland). The anti-transferrin recep-
tor (TfR) mAb H68.4 (IgG1) was provided by Dr. Ian Trowbridge (Salk
Institute, La Jolla, CA) or purchased from Zymed Laboratories, and anti-
HRP was purchased from Jackson ImmunoResearch Laboratories.
 
Cells
 
DHFR-deficient CHO cells stably expressing human CCR5 (CHO-CCR5)
were maintained in nucleoside-free 
 
a
 
MEM with 10% FCS, as described
previously (Mack et al., 1998). CHO cells defective in glycosaminoglycan
(GAG) synthesis (CHO-pgsA-745) and CHO-pgsA-745 expressing human
CCR5 were obtained from Dr. A. Trkola (University Hospital, Zurich,
Switzerland; Trkola et al., 1999). CHO-pgsA-745 cell lines and wild-type
CHO-K1 cells were maintained in DMEM-F12 containing 10% FCS, 2
mM glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomycin.
 
Binding and Elution of 
 
125
 
I-RANTES
and
 
 125
 
I–AOP-RANTES
 
CHO-CCR5 and CHO-K1 cells were plated in 24 
 
3 
 
16–mm well plates
and grown to confluence over 2 d. 
 
125
 
I-labeled chemokines (250 
 
m
 
l at 125
pM), diluted in binding medium (BM: RPMI-1640 without bicarbonate,
containing 0.2% BSA, 10 mM Hepes and adjusted to pH 7.0 or 7.4, as in-
dicated in the text), were added to each well and bound for 90 min at 4
 
8
 
C
on a reciprocal shaker. Subsequently, free ligand was removed by washing
twice with 4
 
8
 
C BM. Half of the wells were then washed twice (3 min each)
with 500 
 
m
 
l pH 2.0 medium (RPMI-1640 without bicarbonate, containing
0.2% BSA, 10 mM MES, and adjusted to pH 2.0) or 500 
 
m
 
l pH 11.6 buffer
(0.25 M NaH
 
2
 
PO
 
4 
 
adjusted to pH 11.6) at 4
 
8
 
C. The cells were washed
again in cold BM, harvested in 400 
 
m
 
l of 0.2 M NaOH, and transferred to
tubes for 
 
g
 
-counting.
 
Internalization of Radiolabeled Chemokines
 
Cells plated in 16-mm wells and grown to 85% confluence over 2 d were
incubated in BM, or BM containing 125 pM 
 
125
 
I-RANTES or 
 
125
 
I–AOP-
RANTES, for 90 min at 4
 
8
 
C. Four wells were used for each time point.
Unbound chemokines were removed by washing with 4
 
8
 
C BM, and the
cells were incubated in 37
 
8
 
C BM for the indicated times. The incubations
were stopped by cooling the plates on ice and washing the cells twice with
4
 
8
 
C BM. To determine the proportion of iodinated ligand internalized
during the 37
 
8
 
C incubation, half the wells for each time point were rinsed
and washed twice (3 min/wash) with pH 11.6 buffer. All wells were then
rinsed with BM and the cells were harvested, as described above. 
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Ligand-induced CCR5 Downmodulation and Recycling
 
Cells were plated, as described above, and incubated in 37
 
8
 
C BM or BM
containing either RANTES (500 nM) or AOP-RANTES (100 nM). After
treatment, the cells were placed on ice and washed four times with 4
 
8
 
C
BM to remove the free chemokine. Selected plates were then incubated in
37
 
8
 
C BM for 1 h and then cooled on ice. The cells were incubated in 4
 
8
 
C
BM containing 6.1 nM 
 
125
 
I–MC-5 for 2 h at 4
 
8
 
C. Finally, all cells were
washed in 4
 
8
 
C BM to remove free antibody, and the cell-associated activ-
ity was measured, as described above.
 
125
 
I–MC-5 Antibody Feeding
 
Cells were treated with RANTES or AOP-RANTES, as described above,
to internalize cell surface CCR5. After endocytosis, all cells were labeled
with 4
 
8
 
C BM, which contained 6.1 nM 
 
125
 
I–MC-5, for 2 h to saturate any
CCR5 receptors remaining at the cell surface. Selected cultures were then
incubated in 37
 
8
 
C BM containing 6.1 nM 
 
125
 
I–MC-5. At the indicated
times, the cells were cooled to 4
 
8
 
C, free antibody was washed away, and
the cell-associated activity was determined, as described above. The cell
protein concentration was determined using bicinchoninic acid (Pierce
and Warriner [UK] Ltd.). Where indicated, 100 
 
m
 
g/ml cycloheximide
(CHX) was included in the medium. At this concentration, CHX blocked
virtually all [
 
35
 
S]methionine/cysteine incorporation in a 5-min pulse label.
 
Western Blotting
 
CHO-CCR5 (6.5 
 
3 
 
10
 
4
 
 cells/well) were grown in 16-mm wells for 2 d. The
cells were washed twice in BM at room temperature and incubated in 250
 
m
 
l of prewarmed BM containing 100 
 
m
 
g/ml CHX without chemokine or
with 500 nM RANTES or 100 nM AOP-RANTES. At the indicated times,
the plates were placed on ice, and the cells were washed twice in 4
 
8
 
C BM
and then in 4
 
8
 
C PBS. Cells were lysed in 100 
 
m
 
l of lysis buffer (1% NP-40,
2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH 8) containing the pro-
tease inhibitors PMSF (1 mM), 5 
 
m
 
g/ml each of chymostatin, pepstatin A,
antipain hydrochloride, and 10 
 
m
 
g/ml leupeptin hemisulphate, as well as
the phosphatase inhibitors sodium orthovanadate (0.1 mM) and sodium
fluoride (50 mM). The wells were scraped and the cell lysates were col-
lected into 1-ml screw cap tubes and left on ice for 30 min. Samples were
centrifuged at 13,000 rpm for 10 min at 4
 
8
 
C, to remove the nuclei and cell
debris, and the supernatants were transferred to new 1-ml tubes. The sam-
ples were either used fresh or frozen at 
 
2
 
70
 
8
 
C. Samples (10 
 
m
 
l of cell ly-
sates) were mixed with 3.3 
 
m
 
l of 4
 
3 
 
reducing SDS sample buffer and 10-
 
m
 
l
aliquots were loaded onto 10% SDS–polyacrylamide gels without boiling.
After electrophoresis, proteins were transferred to nitrocellulose mem-
branes (Schleicher & Schuell). The blots were incubated in blocking
buffer (5% skimmed milk, 5% FCS, 0.1% Tween 20 in PBS) for 1 h and
then in blocking buffer containing 1.1 nM 
 
125
 
I–MC-5 for at least 2 h at
room temperature. Blots were washed four times 10 min each in PBS con-
taining 0.2% Tween 20 and two times 10 min each in PBS containing 0.1%
Tween 20. The blots were left to dry at room temperature and exposed for
a minimum of 6 h to Kodak X-Omat AR film (Eastman Kodak Co.). The
blots were quantitated using a Molecular Imager (Bio-Rad Laboratories).
In addition, bands were cut from the nitrocellulose and 
 
g
 
-counted directly.
Results acquired by both methods were comparable.
 
Immunofluorescence Microscopy
 
CHO-CCR5 cells were grown on coverslips for 2 d. The cells were washed
with BM at room temperature and incubated in 37
 
8
 
C BM with or without
chemokines. Then, the coverslips were placed on ice and washed exten-
sively with cold BM. To study CCR5 receptor recycling, some coverslips
were reincubated at 37
 
8
 
C in BM containing 5 
 
m
 
g/ml of MC-5 for 1 h. The
cells were washed and fixed in PBS containing 3% paraformaldehyde for
10 min. Subsequently, the cells were washed with PBS, the free aldehyde
groups were quenched with 50 mM NH
 
4
 
Cl in PBS, and nonspecific-bind-
ing sites were saturated with PBS containing 0.2% gelatin (PBS/gelatin).
For internal staining, cells were permeabilized during the saturation step
by adding 0.05% saponin into the PBS/gelatin solution. Intact or perme-
abilized cells were labeled for 1 h with MC-5 (5 
 
m
 
g/ml) in PBS/gelatin with
or without 0.05% saponin. The cells were washed to remove free antibody
and then stained with a FITC-conjugated anti–mouse antibody (1:500 in
PBS/gelatin with or without 0.05% saponin; Pierce and Warriner).
For colocalization experiments, cells were labeled with MC-5 (5 
 
m
 
g/ml)
and either 6C4 or 3E9 (1:50 and 1:2 dilutions of hybridoma supernatant,
respectively) in PBS/gelatin. Cells were then stained with a mix of FITC-
conjugated anti–mouse IgG2a (1:100; Nordic Immunological Laborato-
 
ries) and biotin-conjugated anti–mouse IgG1 (1:100; Amersham Pharma-
cia Biotech). Finally, the cells were stained with streptavidin-Texas red
(1:500; Pierce and Warriner). The coverslips were mounted in Mowiol and
examined using a Nikon Optiphot-2 microscope equipped with an MRC
BioRad 1024 confocal laser scanner. The images were assembled using
Adobe Photoshop
 
® 
 
software.
 
Flow Cytometry and FACS
 
® 
 
Analysis
 
CHO-pgsA-745-CCR5 cells were detached in PBS containing 10 mM
EDTA, washed, and resuspended at 10
 
7
 
 cells/ml in BM or BM containing
RANTES or AOP-RANTES at 100 nM. Cells were incubated at 37
 
8
 
C for
1 h, cooled on ice, centrifuged (1,500 rpm, 5 min), and washed three times
in cold BM. For each condition, an aliquot of 100 
 
m
 
l (10
 
6
 
 cells) was washed
in cold PBS and fixed in PBS containing 1% FCS and 1% formaldehyde.
The rest of the cells were centrifuged once more, resuspended in pre-
warmed BM, and incubated for another 60 min at 37
 
8
 
C. Cells were pel-
leted by centrifugation, washed in cold PBS, and fixed as above. After two
washes in PBS containing 1% FCS and 0.05% azide (wash buffer), all cells
were labeled with MC-5 (5 
 
m
 
g/ml in wash buffer) and with a FITC-conju-
gated goat anti–mouse antibody (1:100 in wash buffer) for 1h, and, lastly,
washed three times in wash buffer. Cells were analyzed using a
FACS
 
®
 
Calibur flow cytometer (Becton Dickinson).
 
Immunolabeling of Cryosections for
Electron Microscopy
 
Monolayers of CHO-CCR5 cells in 60- or 90-mm tissue culture dishes
were incubated in BM (pH 7.4) or BM containing 500 nM RANTES or 125
nM AOP-RANTES for 2 or 4 h at 37
 
8
 
C. In one experiment, cells were pre-
treated for 20 min with medium containing BSA conjugated to 5-nm gold
particles (BSA–G
 
5
 
, OD
 
520
 
 
 
5
 
 5) (provided by Dr. Clare Futter, MRC-
LMCB, London, England), then by a 4 h chase in normal medium;
RANTES or AOP-RANTES was added during the last 2 h of the chase.
Early endosomes were labeled with a pulse of HRP (type II at 10 mg/ml),
which was added during the final 5–10 min of the incubation. Cells were
cooled on ice, washed extensively with cold medium, and fixed in 4%
paraformaldehyde alone or together with 0.05 or 0.2% glutaraldehyde.
Fixed cells were washed, embedded in 10% gelatin (ICN Biomedicals), in-
filtrated with 2.3 M sucrose, and frozen in liquid nitrogen, as described pre-
viously (Raposo et al., 1997). Cryosections (
 
z
 
60-nm thick) were labeled
with MC-5 at 1.15 
 
m
 
g/ml (
 
z
 
7.7 nM). In addition, some sections were co-
stained with antibodies against hamster Lgp-B (UH3c), LBPA (6C4),
hamster CD63 (eh1c9b), TfR (H68.4), or HRP. To visualize the mouse
IgG1 antibodies, a bridging rabbit anti–mouse antibody was used (Dako).
Bound antibodies were detected with protein A–gold (EM Lab., Utrecht
University, The Netherlands) and sections were examined with a transmis-
sion electron microscope (EM420; Phillips, Eindhoven, The Netherlands).
 
Online Supplemental Materials
 
125
 
I-RANTES feeding. CHO-CCR5 cells plated in 16-mm wells were
grown to confluence over 3 d. Cells were incubated in pH 7–binding me-
dium (BM; see Materials and Methods) containing 50 nM of RANTES or
AOP-RANTES for 1 h at 37
 
8
 
C (to internalize cell surface CCR5). Subse-
quently, the cells were extensively washed with ice-cold BM and incu-
bated in BM containing 125 pM 
 
125
 
I-RANTES for 2 h at 4
 
8
 
C to equilibrate
CCR5 receptors remaining at the cell surface. One sample for each condi-
tion was left on ice to give the initial cell–associated 
 
125
 
I-RANTES bind-
ing. The other samples were incubated for 10, 30, or 60 min at 37
 
8
 
C in the
continued presence of 
 
125
 
I-RANTES. All cells were then washed four
times with 4
 
8
 
C BM and twice with 4
 
8
 
C PBS. Finally, the cells were har-
vested and the cell-associated radioactivity was determined, as described
in Materials and Methods. Online supplemental material available at http:
//www.jcb.org/cgi/content/full/151/6/1281/DC1.
 
Results
 
Endocytosis and Recycling of CCR5
 
We reported previously that RANTES and AOP-
RANTES downmodulate CCR5 from the surface of pe-
ripheral blood mononuclear cells and transfected CHO
cells (Mack et al., 1998). On cells treated with RANTES, 
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CCR5 recycles to the cell surface after ligand removal.
However, after removal of AOP-RANTES, apparently,
CCR5 is not recycled to the cell surface (Mack et al.,
1998). To understand the cellular basis to these different
effects, we followed CCR5 through the endocytic pathway
after treatment of cells with RANTES or AOP-RANTES.
Both ligands bind to multiple CC chemokine receptors, in-
cluding CCR1, CCR3, and CCR5 (Murphy et al., 2000). In
previous binding studies, radiolabeled MIP-1
 
a
 
 displace-
ment has been used to analyze the binding properties of
RANTES and AOP-RANTES for CCR5 (Simmons et al.,
1997). However, binding studies with these ligands are
complicated, since both can oligomerize and bind GAGs
(Hoogewerf et al., 1997; Oravecz et al., 1997; Ali et al.,
2000). These activities are most pronounced at concentra-
tions of ligand in excess of 1 nM and at pH values 
 
.
 
7.0
(Proudfoot, A.E.I., unpublished data). To facilitate our
studies, we used a CHO cell line stably transfected to ex-
press human CCR5 (Mack et al., 1998). Thus, the only
RANTES/AOP-RANTES binding receptor on these cells
is the CCR5 molecule. Nontransfected CHO-K1 cells were
used throughout as a CCR5-negative control. For some
experiments, we also used CHO–psgA-745 cells that are
defective in GAG synthesis (Trkola et al., 1999). For
experiments with 
 
125
 
I-labeled RANTES and AOP-
RANTES, ligand concentrations of 125 pM were routinely
used in media adjusted to pH 7.0. At this concentration,
ligand oligomerization and GAG binding is minimal, but
receptor occupancy is subsaturating (data not shown). To
saturate cell surface receptors, we routinely used ligands at
100–500 nM in media adjusted to pH 7.0. At this concen-
tration, a significant fraction of the ligand is bound to cell
surface proteoglycans on CHO-CCR5 and -K1 cells, but
receptor downmodulation is maximal (data not shown).
 
In our previous study, we used the mAb MC-1 to moni-
tor ligand-induced CCR5 downmodulation and cycling
(Mack et al., 1998). MC-1 binds to an epitope associated
with the NH
 
2
 
-terminal half of the second extracellular
loop of CCR5, which overlaps the ligand-binding site and
can itself induce CCR5 internalization (Mack, M., unpub-
lished results). Here, we used a second mAb, MC-5, that
binds an epitope associated with the NH
 
2
 
-terminal domain
of human CCR5. This mAb does not induce CCR5 inter-
nalization or affect RANTES binding (Mack, M., unpub-
lished results). MC-5 was radioiodinated and used for
quantitative analysis of CCR5–cell surface expression. Sig-
nificantly, MC-5 could not be eluted from its binding site
at either acidic or basic pH (within the pH range of 2–12)
and, consequently, could not be used to measure endo-
cytosis rates directly. To determine whether CCR5 en-
docytosis and cycling exhibited similar properties when
assessed using MC-5, CHO-CCR5 were treated with
Figure 1. CCR5 downmodulation and recycling. Duplicate sets
of CHO-CCR5 cells were treated with RANTES (500 nM, white
bars) or AOP-RANTES (100 nM, black bars) for 1 h at 378C or
were left untreated (stippled bar). One set of treated cells was
cooled to 48C, whereas the other was washed and incubated in
the absence of ligand for a further 1 h at 378C. Subsequently, all
cells were placed on ice and incubated for 2 h at 48C with 125I–
MC-5. Cell-associated radioactivity was determined as described
in Materials and Methods. The cell-associated counts are ex-
pressed as a percent of the untreated controls. The means and
standard deviations for quadruplicate samples are shown for a
representative experiment.
Figure 2. Binding and internalization of iodinated RANTES
and AOP-RANTES. (A) CHO-CCR5 cells were incubated
with 125 pM 125I-RANTES or 125I–AOP-RANTES for 90 min
at 48C. Bound-radiolabeled ligands (black bars) were eluted
from the cell surface by washes at pH 2 (white bars) or pH 11.6
(stippled bars). The means and standard deviations for tripli-
cate samples are shown for a representative experiment. (B)
125I-RANTES (closed symbols) and 125I–AOP-RANTES
(open symbols) were bound to CHO-CCR5 (j and h) or
CHO-K1 (d,  s) cells as described in A. Cells were then
warmed to 378C for the indicated times, and the ligand re-
maining on the cell surface was removed by treatment with pH
11.6 buffer at 48C, as decribed in A. Each time point indicates
the alkaline resistant (internal) radioactivity as a proportion
of the total cell-associated activity, after subtraction of the
background activity at time zero.Signoret et al. Endocytosis and Recycling of CCR5 1285
RANTES or AOP-RANTES for 1 h at 378C or left un-
treated. The cells were then cooled to 48C or washed and
reincubated in the absence of ligand for 1 h at 378C. Subse-
quently, all cells were incubated at 48C with 125I–MC-5,
and the amount of cell surface bound mAb was deter-
mined, as described in Materials and Methods. Fig. 1 indi-
cates that, as seen previously, both ligands induced down-
modulation of cell surface CCR5, giving a decrease of
65–70% in the level of cell surface receptor. After
RANTES washout, cell surface CCR5 levels recovered by
z50%. In contrast, little recovery (z7%) was detected af-
ter AOP-RANTES removal.
Endocytosis of 125I-labeled RANTES
and AOP-RANTES
To determine the ability of RANTES and AOP-
RANTES to induce endocytosis of CCR5, without the
possible complications of recycling, we developed a di-
rect receptor endocytosis assay using 125I-labeled ligands.
For this assay we needed to distinguish between ligand
located on the cell surface and ligand in intracellular or-
ganelles. In previous endocytosis assays we used low pH
to elute cell surface chemokines (Signoret et al., 1997).
To test the effect of low pH media on RANTES and
AOP-RANTES binding, 125I-labeled ligands were bound
to cells at 48C for 90 min. The cells were then washed and
treated with 48C media adjusted to pH 7.0–2.0. We found
that, though RANTES could be eluted from the cells at
pH values ,4.0, at least 50% of the cell surface AOP-
RANTES remained bound at pH 2.0 (Fig. 2 A). We also
investigated the effect of increasing the pH of the elution
solution. When we used pH 11.6 buffer, .95% of both
ligands were eluted without lysing the cells (Fig. 2 A).
We used these alkaline conditions for the subsequent en-
docytosis assays.
To measure the ability of RANTES and AOP-
RANTES to induce CCR5 endocytosis, radioiodinated
ligands were bound to CHO-CCR5 and CHO-K1 cells on
ice. The cells were then washed and warmed to 378C. At
the indicated times (Fig. 2 B), duplicate samples were re-
turned to 48C. The total cell-associated radioactivity was
determined on one of the samples and the intracellular
activity was determined in the other after pH 11.6 elution
of the cell surface radioactivity. After warming cells to
378C, both RANTES and AOP-RANTES underwent en-
docytosis with equivalent rates (Fig. 2 B). Approximately
70% of the surface-bound ligand was internalized in the
first 5 min after warmup and the amount of internal
ligand reached a maximum at 75–80% by 10 min. The in-
tracellular activity dropped slightly with longer periods
of incubation at 378C (Fig. 2 B). No internalization was
seen for ligands bound to CHO-K1 cells, indicating that
ligand internalization was dependent on binding to
CCR5. Taken together, the data indicate that both
RANTES and AOP-RANTES induce CCR5 endocytosis
with equivalent kinetics.
Figure 3. CCR5 turnover in
ligand-treated CHO cells.
(A) CHO-CCR5 cells were
incubated in BM or BM-con-
taining CHX for up to 9 h at
378C. One tenth of each cell
lysate was loaded per lane
and Western blot analysis
was performed using 125I–
MC-5. Antibody binding was
determined for each band
and is illustrated as the mean 6
SD for three independent ex-
periments, and one represen-
tative blot is depicted. 92 in-
dicates cells incubated in BM
for 9 h without CHX. (B)
Cells were incubated in BM
plus CHX (white bars) or
BM/CHX containing 500 nM
RANTES (gray bars) or 100
nM AOP-RANTES (black
bars) for 1 or 6 h and the
amount of cellular CCR5 was
analyzed as described in A.
Figure 4. Localization of downmodulated CCR5. CHO-CCR5
cells were treated with RANTES (500 nM) for 4 h at 378C. After
fixation and permeabilization, the cells were stained for CCR5
and the lysosomal markers LBPA (A) and Lgp-B (B), respec-
tively. Open arrowheads indicate CCR5-positive, but LBPA- or
Lgp-B–negative, vesicles; white arrowheads indicate LBPA- (A)
or Lgp-B–positive (B), but CCR5-negative, late endocytic struc-
tures. Bar, 10 mm.The Journal of Cell Biology, Volume 151, 2000 1286
Figure 5. Ultrastructural localization of CCR5. CHO-CCR5 cells were pulsed with BSA–gold (5 nM, BSA–G5) for 20 min and chased
with medium for 4 h to mark late endocytic organelles. Cells were treated with 500 nM RANTES (A and D) or 125 nM AOP-RANTES
(B, C, E, and F) during the last 2 h of this chase, washed, and processed for cryosection immunolabeling EM. CCR5 was detected by
staining with MC-5 and 10 nm (B) or 15 nm (A and C–F) protein A–gold particles. cp, coated pit; G, Golgi complex. C–F show double
label staining of sections for CCR5 (15 nm gold particles, large arrows) with the markers of the endocytic pathway Lgp-B (C), CD63Signoret et al. Endocytosis and Recycling of CCR5 1287
(D), or the TfR (E and F) labeled with 10 nM gold particles (small arrows). BSA–G5–containing late endocytic vacuoles are marked
with an asterisk. The CCR5-containing tubules and vesicles are distinct from the organelles labeled with Lgp-B (C) or CD63 (D), even
though these markers can occasionally be observed in the same part of the cell. In contrast, the TfR-containing tubules are intermingled
with MC-5–labeled tubules and vesicles (E and F), with the large and small gold particles are occasionally found in the same vesicles.
Note the prominent coats on some of the CCR5-containing vesicles (open arrowheads in C–E). Bars, 200 nm.
CCR5 Turnover
In many cases, ligand-induced receptor internalization can
lead to the delivery of receptors to hydrolytic compart-
ments of the endocytic pathway, where they are degraded.
To determine whether either RANTES or AOP-RANTES
caused enhanced degradation of CCR5, we examined the
turnover of this receptor on ligand-treated and -untreated
cells. The MC-5 antibody effectively detected CCR5 in
Western blot analysis (Fig. 3). Therefore, we treated cells
with CHX for up to 9 h to block protein synthesis, and
then analyzed cell lysates by SDS-PAGE and Western
blotting using 125I–MC-5. Initial experiments indicated that
the cellular CCR5 content decreased with a half-time of
6–9 h in these transfected-CHO cells (Fig. 3 A), similar to
previous reports (Mirzabekov et al., 1999). When cells
were treated with RANTES or AOP-RANTES for either
1 or 6 h, the electrophoretic mobility of CCR5 decreased
(Fig. 3 B). This apparent increase in molecular weight cor-
relates with ligand-induced serine phosphorylation in the
cytoplasmic COOH-terminal domain of CCR5 (Opper-
mann et al., 1999). However, the amount of CCR5 in sam-
ples from ligand-treated cells was similar to that recovered
from untreated cells (Fig. 3 B). The data indicate that nei-
ther RANTES nor AOP-RANTES significantly affect the
turnover of CCR5 and that ligand-induced endocytosis
does not lead to increased CCR5 degradation.
Location of Internalized CCR5
The finding that RANTES and AOP-RANTES induced
rapid endocytosis of CCR5, but did not affect the rate of
turnover of the receptor, prompted us to look closely at the
intracellular distribution of CCR5 after ligand-induced in-
ternalization. Using immunoflurescence, we found previ-
ously that after 1-h treatment with saturating concentrations
of ligand, most CCR5 was redistributed from the cell sur-
face and was seen in endosomal elements that overlapped
with vesicles containing TfR. There was little detectable de-
livery of internalized CCR5 to vesicles that labeled for the
lysosomal membrane glycoprotein Lgp-B (Lgp-120) (Mack
et al., 1998). To determine whether longer incubations with
ligand changed the distribution of CCR5, we treated CHO-
CCR5 cells for 4 h or overnight at 378C with RANTES or
AOP-RANTES. Cells were then fixed, permeabilized, and
stained for CCR5 and markers of late endosomes and lyso-
somes, Lgp-B, and LBPA (Kobayashi et al., 1998). Fig. 4
shows cells labeled after 4 h of RANTES treatment. CCR5
was detected primarily in intracellular structures located in
the perinuclear region. These were mostly distinct from
LBPA-containing vesicles that were also located around the
nucleus. Similarly, staining with anti–Lgp-B indicated that
after longer periods of ligand treatment little CCR5 was lo-
cated in late endosomes and lysosomes. The distribution
was indistinguishable for cells treated with AOP-RANTES
and for cells treated overnight with either ligand (data not
shown). Together with the turnover data (Fig. 3), these re-
sults indicate that neither RANTES nor AOP-RANTES in-
duce the accumulation of internalized CCR5 into late endo-
somes or lysosomes.
Ultrastructural Localization of Internalized CCR5
To identify the subcellular compartment(s) in which inter-
nalized CCR5 accumulated, we used immunolabeling of
ultrathin cryosections and EM. MC-5 can label CCR5 on
cryosections, even after fixation in solutions containing up
to 0.2% glutaraldehyde, and can interact directly with pro-
tein A–gold. Labeling of untreated cells demonstrated that
CCR5 is localized almost exclusively at the plasma mem-
brane, including microvilli (not shown). Nonspecific bind-
ing, indicated by gold particles over the nucleus, or on
CHO-K1 cells, was very low (not shown). Within minutes
of treatment with RANTES or AOP-RANTES, CCR5
could be seen in coated vesicles and tubular vesicular pro-
files similar to those described for sorting endosomes (data
not shown). When cells were treated with RANTES or
AOP-RANTES for 2 or 4 h, CCR5 was relocated from the
plasma membrane into intracellular structures. Most of the
internalized CCR5 was observed in small membrane-
bound vesicles and tubules of z50-nm diameter (Fig. 5, A
and B). These tubules and vesicles were often clustered in
the perinuclear area of the cell and frequently close to
stacked cisternae of the Golgi apparatus. At least 60% of
all internalized CCR5 was found over such small tubules
and vesicles. A smaller proportion of the internalized
CCR5 (,20%) could also be observed in larger vacuoles,
which were usually devoid of content or contained one or a
few internal vesicles.
We used antibody markers to identify specific endocytic
compartments in double-staining studies together with
MC-5. Late endocytic structures and lysosomes were
marked by feeding cells BSA coupled to 5-nm gold (BSA–
G5) for 20 min followed by a 4 h chase in normal medium;
RANTES or AOP-RANTES was added during the last 2 h
of the chase. Here, ,2% of intracellular-labeled CCR5
molecules were seen in BSA–gold-containing structures
(Fig. 5, C and D). Furthermore, double-labeling studies
showed that there was little colocalization of CCR5 with
Lgp-B (Fig. 5 C), CD63 (Fig. 5 D), or LBPA (not shown).
These EM studies support the notion that internalized
CCR5 is not delivered to late endosomes or lysosomes af-
ter treatment of cells with RANTES or AOP-RANTES.
To determine whether CCR5 accumulates in early endo-
somes in ligand-treated cells, cells were pulsed with the
fluid-phase marker HRP for 5 or 10 min at the end of the
incubations with RANTES or AOP-RANTES. Internal-
ized HRP was detected with a rabbit polyclonal anti-HRP
antibody and protein A–gold. Internalized HRP was also
found in small vesicles or tubules that were usually located
in the periphery of the cell close to the plasma membrane,
and were distinct from the more perinuclear clusters of
vesicles containing CCR5 (not shown). Occasional MC-5The Journal of Cell Biology, Volume 151, 2000 1288
labeling was seen in larger (0.2–0.5-mm diameter) empty
vacuoles that contained HRP. However, the majority of
the two labels was distinct.
The distribution of CCR5 in tubules and vesicles clus-
tered in the vicinity of the Golgi apparatus suggested that
CCR5 may accumulate in recycling endosomes (Yama-
shiro et al., 1984; Hopkins et al., 1994). The TfR also traf-
fics through this juxtanuclear compartment and is found
primarily within recycling endosomes in CHO cells (Ya-
mashiro et al., 1984). To determine whether CCR5 is asso-
ciated with recycling endosomes in RANTES or AOP-
RANTES–treated cells, cryosections were costained with
the anti-TfR antibody H68.4 and with MC-5. The TfR was
also seen to be located in clusters of small vesicles and tu-
bules frequently close to stacks of Golgi cisternae. Signifi-
cant overlap between the TfR and CCR5 was seen (Fig. 5,
E and F). Due to the low density of gold particles, the two
markers were only occasionally seen together in the same
vesicles. Nevertheless, the accumulation of both CCR5
and TfR in the same clusters of vesicles indicates that
CCR5 does indeed enter the recycling endosome. More-
over, as the distribution of internalized CCR5 was indistin-
guishable in RANTES- or AOP-RANTES–treated cells,
both ligands appear to induce redistribution of CCR5
from the cell surface to recycling endosomes.
Significantly, some CCR5 was seen at the plasma mem-
brane even after 2 or 4 h treatment with RANTES or AOP-
RANTES, and CCR5 could be found in coated-pit and
coated-vesicle profiles at these times (Fig. 5 B). The signifi-
cance of these observations is discussed in more detail below.
CCR5 Recycling
The observations that (a) both RANTES and AOP-
RANTES induce redistribution of CCR5 to recycling en-
dosomes, (b) CCR5 appears to recycle to the cell surface
only after RANTES washout, and (c) CCR5 can be found
in coated vesicles even after 2 or 4 h of AOP-RANTES
treatment prompted us to reinvestigate the recycling of
CCR5. Our previous recycling assays would detect recep-
tors that recycle to the cell surface and remain there. How-
ever, it would not detect receptors that recycle and then re-
internalize. Alternatively, AOP-RANTES may selectively
induce the sequestration of CCR5 in recycling endosomes.
To investigate these alternatives we performed antibody
feeding experiments in which cells that had been treated
with chemokine were washed to remove free chemokine
and then reincubated at 378C in the presence of MC-5. For
cells to be labeled with MC-5 during this incubation, CCR5
must return to the plasma membrane and be exposed to
the extracellular medium containing the antibody.
We first monitored CCR5 cycling by immunofluores-
cence. CHO-CCR5 cells were incubated for 1 h at 378C in
normal medium or medium containing RANTES or AOP-
RANTES. The cells were then placed on ice and washed
extensively with cold medium. At this stage, some cells
were fixed, labeled with MC-5, and stained with a fluores-
cent anti–mouse antibody to assess the efficiency of
chemokine-induced CCR5 internalization. The rest of the
cells were incubated for a further 1 h at 378C in ligand-free
medium containing MC-5. Subsequently, these cells were
washed in cold medium, fixed, and labeled with only the
fluorescent anti–mouse reagent with or without permeabi-
lization with saponin. With untreated cells, MC-5 staining
indicated that the majority of CCR5 was located at the cell
surface and there was little detectable intracellular stain-
ing (Fig. 6 A). Treatment with RANTES or AOP-
RANTES induced redistribution of the bulk of CCR5
from the cell surface to intracellular organelles (Fig. 6 A).
When RANTES was washed away and the cells fed with
MC-5, we observed a recovery of the cell surface staining
visible on intact cells, indicating that some CCR5 recep-
tors had recycled to the plasma membrane (Fig. 6 B). In
addition, permeabilized RANTES-treated cells showed
some internal punctate staining, suggesting that some
CCR5 labeled with MC-5 antibodies had reinternalized
into intracellular vesicles (Fig. 6 B).
In keeping with previous results (Mack et al., 1998), little
cell surface staining was seen on AOP-RANTES–treated
cells fed with MC-5. However, prominent intracellular
perinuclear staining was observed on permeabilized cells
(Fig. 6 B). This pattern was similar to that seen with cells
fixed and stained at the end of the initial AOP-RANTES
treatment (Fig. 6 A). If the receptors internalized during
the AOP-RANTES treatment were sequestered in an en-
Figure 6. Recycling of CCR5. (A) CHO-CCR5
cells were incubated in BM or BM with 100 nM
RANTES or 100 nM AOP-RANTES for 1 h at
378C. Cells were then fixed and stained with
MC-5 and a FITC-conjugated goat anti–mouse
antibody. Cells were stained intact to show cell
surface CCR5 or after permeabilization to show
intracellular plus cell surface CCR5 (Total). (B)
CHO-CCR5 cells were initially treated with
RANTES or AOP-RANTES as in A, but after
downmodulation, the cells were washed exten-
sively at 48C in BM, and then incubated in BM
containing MC-5 for 1 h at 378C. The cells were
then fixed and stained intact, or after permeabili-
zation with Saponin, with the FITC-conjugated
anti–mouse antibody. Bar, 20 mm.Signoret et al. Endocytosis and Recycling of CCR5 1289
docytic compartment, they should not have access to the
extracellular MC-5. The finding that AOP-RANTES–
treated cells can be labeled with MC-5 indicates that, even
on these cells, CCR5 has recycled to the cell surface where
it encountered MC-5 and was then reinternalized. The fact
that fluid-phase markers are not delivered efficiently to re-
cycling endosomes (Sheff et al., 1999), as indicated by the
HRP uptake (see above), and that untreated CHO-CCR5
cells fed with MC-5 show only cell surface staining (Fig. 6
B) makes it unlikely that this labeling could have occurred
by fluid-phase endocytosis of MC-5.
Biochemical Analysis of CCR5 Recycling
To examine CCR5 cycling quantitatively, we performed
similar antibody feeding experiments using 125I–MC-5.
CHO-CCR5 cells were treated with medium or medium
containing either RANTES or AOP-RANTES for 1 h at
378C. The cells were then labeled with saturating concen-
trations of 125I–MC-5 for 2 h at 48C to block all cell surface
MC-5–binding sites. Subsequently, the cells were washed
with cold medium to remove the excess antibody. One
sample for each condition was left on ice to give the
amount of antibody bound to the cell surface after CCR5
downmodulation. The other samples were incubated for
1 h at 378C in the continued presence of 125I–MC-5. Sub-
sequently, all the cells were washed and the cell-associ-
ated radioactivity was determined. RANTES and AOP-
RANTES treatment induced 65–70% CCR5 downmodu-
lation, respectively (Fig. 7 A). Since 30–35% of the initial
cell surface pool of CCR5 remained at the plasma mem-
brane, the initial incubation with 125I–MC-5 at 48C satu-
rated these sites and enabled us to quantitate any internal
receptor that recycled to the cell surface. This experiment
does not discriminate between recycling receptors that re-
main at the plasma membrane and recycled receptors that
are rapidly reinternalized, rather it assesses the total num-
ber of receptors recycling from endosomes. With both
RANTES and AOP-RANTES–treated cells, the total
counts detected after 1 h of 125I–MC-5 feeding at 378C
were z70% of the counts initially bound to the surface of
untreated cells (Fig. 7 A). This indicates that at least 35–
40% of the receptors that were internalized during the ini-
tial exposure to the chemokines were able to recycle when
the chemokine was removed. Moreover, no significant dif-
ference was seen for cells treated with RANTES versus
cells treated with AOP-RANTES. Similar results were ob-
tained when the experiment was done using cells that had
been treated with CHX before the start of the assay and
throughout the course of the experiment, ruling out the
possibility that uptake of MC-5 occurred on newly synthe-
sized CCR5 molecules (Fig. 7 A).
To investigate the kinetics of CCR5 recycling after
treatment with RANTES or AOP-RANTES, we analyzed
125I–MC-5 feeding on CHO-CCR5 cells for up to 60 min
after ligand-induced downmodulation. In these experi-
ments, MC-5 labeling of ligand treated or untreated cells
were compared. For the latter cells, recycling should not
occur, but the initial labeling with 125I–MC-5 would be pre-
dicted to be high. Therefore, we plotted the data for each
time point relative to the cell-associated activity after the
initial 125I–MC-5 labeling at 48C. Fig. 7 B shows a rapid in-
crease in 125I–MC-5 labeling for cells exposed to ligand,
with virtually identical rates of labeling for RANTES and
AOP-RANTES–treated cells.
Since removal of RANTES allowed CCR5 to recycle to
the cell surface after the initial endocytosis, we asked if
this CCR5 is sensitive to a second exposure to RANTES,
as already observed on primary cells (Mack et al., 1998).
CHO cells expressing CCR5 were treated in suspension
with RANTES for 1 h at 378C, or left untreated. The cells
were then cooled to 48C or washed and reincubated in the
absence of ligand for 1 h at 378C. Some cells were then
treated with RANTES for a second time. Cell surface ex-
pression of CCR5 was monitored on fixed cells using MC-5
and analyzed by flow cytometry. This type of experiment
was performed on different CHO-CCR5 lines with similar
results, and Fig. 8 B shows one of these experiments done
with CHO-pgsA-745 CCR5 cells (see below). The increase
in fluorescence intensity seen after removal of the ligand
was lost after the second treatment with RANTES, indi-
cating that recycled CCR5 molecules are sensitive to a sec-
ond round of RANTES-induced internalization.
Figure 7. Quantitative analysis
of  125I–MC-5 feeding. CHO-
CCR5 cells were incubated in
BM (white bars, and h) or BM
containing RANTES (500 nM,
gray bars and d) or AOP-
RANTES (100 nM, black bars
and m) for 1 h at 378C. CCR5
molecules remaining at the
plasma membrane were then la-
beled on ice with 125I–MC-5 to
determine the extent of down-
modulation. After this satura-
tion step, some cells were rein-
cubated in prewarmed medium
containing  125I–MC-5 to allow iodinated antibody to label recycling CCR5. (A) Cells were fed with the 125I–MC-5 for 1 h in the presence
or absence of CHX. The graph indicates the cell-associated radioactivity for each point as a percent of the radioactivity bound on un-
treated cells and is the mean 6 SD for triplicate samples. (B) To determine the kinetics of 125I–MC-5 uptake, cells were fed with 125I–
MC-5 for various times after washing out RANTES or AOP-RANTES. The graph shows the relative increase in cell-associated radio-
activity at each time point, calculated by dividing the total cell-associated radioactivity at each time point by the cell-associated activity
at time zero. Each point represents the mean 6 SD of triplicate samples from a representative experiment.The Journal of Cell Biology, Volume 151, 2000 1290
Taken together, the antibody feeding assays indicate that
CCR5 can recycle to the cell surface after washout of both
RANTES and AOP-RANTES. Moreover, the extent and
kinetics of recycling appear to be similar after treatment
with either ligand. However, on AOP-RANTES–treated
cells, the recycled CCR5 continues to undergo endocytosis.
As a consequence, the major steady-state pool of CCR5 is
relocated from the cell surface to recycling endosomes.
Cell Surface Proteoglycans Do Not Influence
CCR5 Cycling
In addition to their high affinity for CCR5, RANTES and
AOP-RANTES can bind to GAG, such as heparan sulfate
(Kuschert et al., 1999; Trkola et al., 1999). It has been sug-
gested that GAG binding may serve to increase the local
concentration of chemokines on the cell surface by induc-
ing chemokine oligomerization (Hoogewerf et al., 1997).
As many of the experiments discussed above used high
concentrations of ligand in which significant cell surface
GAG binding could have occured, we sought to determine
whether cell surface GAGs might influence the internal-
ization and recycling of CCR5 seen on CHO cells. CHO-
pgsA-745, a CHO line defective in GAG synthesis (Esko
et al., 1985; Trkola et al., 1999), and CHO-pgsA-745–
expressing human CCR5 were treated in suspension with
RANTES or AOP-RANTES for 1 h to induce CCR5
downmodulation. The cells were then washed and some
cells were reincubated at 378C for 1 h in ligand-free me-
dium. Cell surface expression of CCR5 was detected by
immunofluorescence using MC-5 and was analyzed by
flow cytometry. As shown in Fig. 8 A, both RANTES and
AOP-RANTES induced CCR5 downmodulation on the
transfected CHO-pgsA-745 cells, indicating that the ab-
sence of GAG did not interfere with the activity of the
chemokines. Furthermore, by 1 h after the removal of
RANTES, a large part of the CCR5 molecules had recy-
cled to the cell surface (Fig. 8, A and B). In contrast, and
in keeping with the CHO-CCR5 cells, no significant recov-
ery of cell surface–CCR5 expression was seen on AOP-
RANTES–treated cells (Fig. 8 A). Nevertheless, feeding
of MC-5 after washout of AOP-RANTES showed uptake
of the antibody and an intracellular fluorescent pattern
(Fig. 8 C) similar to that described for CHO-CCR5 cells
(Fig. 6 B). These results indicate that the binding of
RANTES and AOP-RANTES to GAG is not required for
either CCR5 internalization or recycling.
Discussion
Interest in chemokines and chemokine receptors has been
prompted by the recent discovery that these proteins play
important roles not only in inflammation and regulation of
immune responses, but also in the entry and pathogenesis of
the primate immunodeficiency viruses (Murphy et al.,
2000). Considerable effort has been directed towards un-
derstanding the binding properties and specificities of these
molecules and to the development of antagonists for spe-
cific chemokine receptors (Baggiolini et al., 1997; Murphy
et al., 2000). However, relatively little attention has been
paid to understanding the trafficking properties of chemo-
kine receptors and the mechanisms through which traffick-
ing pathways are coupled to receptor downmodulation, sig-
nal transduction, and other functions of these proteins.
Recently, we and others demonstrated that ligand-induced
endocytosis of CXCR4 and CCR5 plays a major role in the
mechanisms through which chemokines protect cells from
HIV infection (Amara et al., 1997; Signoret et al., 1997).
This conclusion was subsequently supported by the obser-
Figure 8. Downmodulation and recycling of CCR5 on CHO cells
deficient in GAG synthesis. (A) CHO-pgsA-745–expressing CCR5
(medium) were treated in suspension with 100 nM RANTES or 100
nM AOP-RANTES for 1 h (ligand). After washout of the chemo-
kines, some cells were incubated in fresh medium for a further 1 h
(ligand, washout). Cells were then fixed and stained with MC-5 and
FITC-conjugated anti–mouse antibody and the level of cell-surface
fluorescence was measured by flow cytometry. Cells labeled with the
secondary antibody only were used as a negative control (shaded
peak). (B) CHO-pgsA-745-CCR5 cells were incubated in medium
alone (medium) or medium containing 100 nM RANTES for 1 h
(RANTES). Excess chemokine was removed by washing and the
cells were incubated in fresh medium for one more hour (RANTES,
washout). Cells were then treated for a second time with medium
containing 100 nM RANTES for 1 h (RANTES, washout,
RANTES). Finally, cells were fixed, stained, and analyzed, as de-
scribed in A. (C) CHO-pgsA-745-CCR5 cells were incubated in me-
dium alone (left) or medium containing 100 nM AOP-RANTES
(right) for 1 h. Excess chemokine was removed by washing and then
the cells were fed with MC-5 for 1 h at 378C. Cells were fixed, per-
meabilized, and stained with the FITC-conjugated anti–mouse anti-
body. Bar, 20 mm.Signoret et al. Endocytosis and Recycling of CCR5 1291
vation that the effective anti-HIV activity of a chemically
modified form of the CC chemokine RANTES, AOP-
RANTES, correlated with the ability of this ligand to in-
duce efficient and apparently irreversible downmodulation
of CCR5 (Simmons et al., 1997; Mack et al., 1998). More-
over, recent data have suggested that the ability of chemo-
kines produced in vivo to downmodulate chemokine-recep-
tor expression on target cells for HIV infection may have a
significant influence on viral transmission and the course of
pathogenesis (Agace et al., 2000). Here, we have inves-
tigated the cell biological mechanism(s) through which
RANTES and AOP-RANTES differentially downmodu-
late cell surface–CCR5 expression. In particular, we sought
to understand why CCR5 internalized in the presence of
RANTES can be reexpressed on the cell surface when the
ligand is removed, but CCR5 internalized in the presence of
AOP-RANTES is not. Our data indicate that this effect is
due to an irreversible, or only slowly reversible, activation
of CCR5 endocytosis by AOP-RANTES.
AOP-RANTES was initially characterized as a RANTES
receptor antagonist due to its ability to inhibit chemotaxis
induced by RANTES and MIP-1b (Simmons et al., 1997).
Subsequent studies indicated that though it is a weak
partial agonist for CCR1 and CCR3, AOP-RANTES is in
fact a full agonist for CCR5 and can induce calcium flux,
GPCR kinase (GRK)–mediated receptor phosphoryla-
tion, and receptor endocytosis (Mack et al., 1998; Opper-
mann et al., 1999; Proudfoot et al., 1999; Elsner et al.,
2000). In these activities, AOP-RANTES is similar to
RANTES. Nevertheless, AOP-RANTES is clearly more
effective in blocking CCR5-dependent HIV entry than na-
tive RANTES (Simmons et al., 1997; Mack et al., 1998).
However, the activities of AOP-RANTES on other
chemokine receptors, including CCR1 and CCR3, are dis-
tinctly different and the properties described here for
CCR5 do not extend to other receptors. Moreover, though
more effective than RANTES on CCR5, AOP-RANTES
does not block entry of CCR3 tropic HIV-1 strains (Elsner
et al., 2000).
Ligand-induced endocytosis of CCR5 is believed to in-
volve mechanisms similar to those described for the b2-
adrenergic receptor (b2AR) (Lefkowitz, 1998). Ligand
binding induces receptor phosphorylation, calcium influx,
G protein activation, GRK-dependent recruitment of a
nonvisual arrestin, and internalization (Aramori et al., 1997;
Oppermann et al., 1999; Rodriguez-Frade et al., 1999; Vila-
Coro et al., 1999). b-Arrestin 1 and 2 have been implicated
in coupling activated b2AR and other GPCRs to clathrin
and the endocytosis of these receptors through clathrin-
coated pits (Ferguson et al., 1996; Goodman et al., 1997;
Krupnick et al., 1997). Inhibitor studies (Mack et al., 1998),
together with the transient expression of exogenous or
dominant-negative GRKs and/or arrestins (Aramori et al.,
1997) and the morphological experiments reported here,
have indicated that CCR5 is also endocytosed through a
mechanism that involves nonvisual arrestins and clathrin-
coated vesicles. The subsequent fate of CCR5 is less well es-
tablished. We showed previously that the distribution of in-
ternalized CCR5 overlaps closely with that of endosomal
markers, in particular the TfR, and that, at least after
RANTES washout, CCR5 can recycle to the cell surface.
The binding of AOP-RANTES to CCR5, measured by
displacement of radiolabeled MIP-1a,  indicates a single
high affinity–binding site with an inhibitory concentration
of 50% (IC50) of 0.072 nM, whereas RANTES displayed a
two component displacement curve, suggesting both a
high and a low affinity site with affinities of 0.022 and 18
nM, respectively (Simmons et al., 1997). AOP-RANTES
also appears to induce higher levels and more sustained
phosphorylation of CCR5 compared with RANTES (Op-
permann et al., 1999; Vila-Coro et al., 1999). However, the
roles of these events in the irreversible loss of CCR5 cell
surface expression by AOP-RANTES remain to be es-
tablished. Moreover, the ability of both RANTES and
AOP-RANTES to oligomerize and bind proteoglycans
(Hoogewerf et al., 1997; Kuschert et al., 1998) makes the
interpretation of some of these observations problematic.
Here, we show that radiolabeled RANTES and AOP-
RANTES, bound at subsaturating concentrations, are en-
docytosed with very similar kinetics on CCR5-transfected
CHO cells. More than 70% of the ligand bound at 48C is
internalized in 5 min after warming cells to 378C. Approxi-
mately 70–80% of the bound material was endocytosed by
10 min, but internal radioactivity levels then dropped to
z60% by 30 min. Whether this drop represents recycling
of internalized ligand–receptor complexes has yet to be es-
tablished, but is consistent with the observation that CCR5
can recycle on both RANTES and AOP-RANTES–
treated cells. After internalization, CCR5 molecules are
delivered to early endosomes. We show that neither
RANTES nor AOP-RANTES affects the constitutive
turnover of the CCR5 protein. Even 6 h after treating cells
with saturating concentrations of ligand, similar levels of
protein are seen in treated and untreated cells.
Using both immunofluorescence and immunolabeling of
cryosections and EM, we found that most CCR5 molecules
were initially located on the surfaces of untreated cells.
Early after treatment with RANTES or AOP-RANTES,
CCR5 was seen in coated vesicles and tubular vesicular
profiles similar to those described for sorting endosomes
(Marsh et al., 1986; Griffiths et al., 1989). After 2 h, some
labeling was still seen at the cell surface by EM, consistent
with biochemical experiments that indicated that only 70–
80% of cell surface CCR5 was downmodulated by either
RANTES or AOP-RANTES. At 2 h, most of the intra-
cellular CCR5 labeling in both RANTES and AOP-
RANTES–treated cells was seen to be associated with
clusters of small tubules and vesicles, often located close to
stacks of Golgi cisternae. At these times, little CCR5 was
seen in sorting endosomes, marked with internalized HRP,
and only occasional labeling was seen in late endocytic
compartments, marked with either internalized BSA–gold
or antibodies directed against three antigens found in late
endosomes and lysosomes (Lgp-B/Lgp-120, CD63, and
LBPA). Recycling endosomes were initially described in
CHO cells, and they were observed as a perinuclear com-
partment where the bulk of the TfR is located and where
internalized transferrin can be seen after endocytosis (Ya-
mashiro et al., 1984). The compartment was subsequently
seen by EM to consist of clusters of small 60-nm diameter
vesicles and tubules (Hopkins et al., 1994). The tubular ve-
sicular clusters in which we observe internalized CCR5
were not labeled with fluid-phase markers, but were la-
beled with antibodies directed against the cytoplasmic do-
main of the TfR. By the criteria currently available, these
structures have the characteristics of recycling endosomes.The Journal of Cell Biology, Volume 151, 2000 1292
Thus, we propose that RANTES or AOP-RANTES–
bound CCR5 molecules are internalized via clathrin-
coated vesicles, delivered initially to sorting endosomes,
and then directed to recycling endosomes. Although many
GPCRs, including b2AR, have been shown to undergo en-
docytosis and recycling, this is the first demonstration of
which we are aware that indicates a role for the recycling
endosome compartment in the trafficking of a GPCR.
The finding that both RANTES and AOP-RANTES in-
duced relocation of CCR5 from the cell surface to recycling
endosomes caused us to reexamine the finding that AOP-
RANTES induces irreversible downmodulation of CCR5
(Mack et al., 1998). If the AOP-RANTES–induced CCR5
downmodulation cannot be reversed after ligand washout,
this ligand must cause the receptor to be sequestered within
recycling endosomes. To address this issue, we used anti-
body feeding experiments to investigate whether CCR5
might be recycled and then reinternalized in AOP-
RANTES–treated cells. After washing out the ligand from
RANTES-treated cells and incubating the cells in ligand-
free medium containing MC-5 for 1 h at 378C, we found that
the antibody was located both at the cell surface and within
punctate cytoplasmic organelles. This is consistent with pre-
vious observations that CCR5 can recycle on RANTES-
treated cells. We also found MC-5 labeling in cells that had
been treated with AOP-RANTES. However, this labeling
was largely confined to intracellular compartments with a
distribution indistinguishable from that seen after AOP-
RANTES–induced CCR5 downmodulation. The most
likely way for this CCR5 to have become labeled is for
CCR5 to have recycled to the cell surface, become labeled
with mAb, and then rapidly reinternalized. Quantitative
analysis using iodinated MC-5 indicated that the extent of
MC-5 labeling and the kinetics of labeling were very similar
for both RANTES and AOP-RANTES–treated cells. Thus,
CCR5 recycling is similar on cells treated with RANTES
and AOP-RANTES, except that on AOP-RANTES–
treated cells receptors that reappear on the cell surface are
rapidly reinternalized. The fact that the rate of 125I–MC-5 la-
beling is the same on both RANTES and AOP-RANTES–
treated cells argues against labeling of intracellular CCR5 by
fluid-phase endocytosis of radiolabeled antibody. Moreover,
previous studies have indicated that fluid-phase markers do
not access recycling endosomes efficiently (Sheff et al.,
1999). Finally, we observed CCR5 in clathrin-coated pits
even after 4 h of AOP-RANTES treatment, which is consis-
tent with the notion that this receptor undergoes rounds of
endocytosis and recycling. Taken together, the data indicate
that CCR5 recycles to the cell surface after removal of
ligand from RANTES-treated cells and that recycling is un-
impaired on AOP-RANTES–treated cells. The principal
difference in the two ligands is that the ligand-induced con-
version of CCR5 to a form that undergoes efficient endocy-
tosis can be reversed when RANTES is washed out, but not
when AOP-RANTES is removed. Thus, a stable, or only
slowly reversible, AOP-RANTES–induced activation of
CCR5 leads to the relocation of the cell surface pool of
CCR5 to the recycling endosome compartment.
The mechanism through which AOP-RANTES irrevers-
ibly activates CCR5 endocytosis remains unclear. For other
GPCRs, such as the b2AR, trafficking through endosomes
has been linked to acid-induced receptor–ligand dissociation
(Krueger et al., 1997; Lefkowitz, 1998). Although we found
some differences in the pH dependence of RANTES or
AOP-RANTES dissociation from CCR5, neither ligand ex-
hibited significant release at pH values above 4, i.e., within
the pH range found in endocytic organelles. However, we
have shown that the CCR5 that recycles to the cell surface
after RANTES removal is resensitized and can be reinter-
nalized when the cells are exposed to a second round of
RANTES. Thus, trafficking of RANTES-occupied CCR5 to
recycling endosomes presumably leads to removal of at least
some of the ligand from CCR5 and allows resensitized re-
ceptors to recycle to, and reaccumulate on, the cell surface.
Preliminary 125I-RANTES feeding experiments, similar to
those illustrated here for 125I–MC-5, indicate that only
CCR5 molecules that recycle after RANTES washout are
able to bind the iodinated ligand. CCR5 recycling after
AOP-RANTES removal does not bind 125I-RANTES (see
Online Supplemental Materials), suggesting that in this case
the receptor may still be occupied, preventing further ligand
binding. Sustained binding of AOP-RANTES, or an AOP-
RANTES fragment, may maintain the receptor in a form
that is recognized by the endocytic machinery, relocating the
major steady-state pool of CCR5 to recycling endosomes.
Although these mechanisms remain to be clarified in de-
tail, we show that CCR5 is recycled efficiently in both
RANTES and AOP-RANTES–treated cells. Moreover,
the recycling of CCR5 in cells treated with AOP-RANTES
may not be coupled to receptor resensitization. In this re-
spect, the recycling of CCR5 appears to differ from that
described for GPCRs, such as b2AR. In the latter case, en-
docytosis and trafficking through endosomes is required
for ligand dissociation, receptor dephosphorylation, and
recycling of resensitized receptors to the cell surface
(Krueger et al., 1997; Lefkowitz, 1998). Whether these re-
ceptors also undergo recycling and reinternalization if
ligand is not removed, as appears to be the case for CCR5,
is unclear. However, one implication of our data is that
CCR5 recycling may not be regulated through the ability
of endosomes to distinguish receptors that have been re-
sensitized by ligand removal from receptors that remain at
least partially activated. Rather, receptors may recycle at
similar rates regardless of their activation state. Thus, tran-
sit through an endosome compartment may be necessary
to remove ligand and resensitize receptors, but in the event
that this does not occur, activated receptors that recycle to
the cell surface are rapidly reinternalized and reexposed to
the endosome environment. Therefore, resensitization for
CCR5 may be an iterative process requiring multiple cy-
cles through the endosome compartment.
Finally, with regard to the ability of AOP-RANTES to
protect cells from HIV infection, both RANTES and
AOP-RANTES can downmodulate the cell surface ex-
pression of CCR5. At present, we know little of the re-
quirements, in terms of receptor density, for HIV entry.
The fact that the effects of AOP-RANTES appear at best
to be only slowly reversible may be an important compo-
nent of its increased efficacy. Our data suggest that a small
molecular therapeutic agent aimed at preventing HIV en-
try would be most effective if it could mimic the properties
displayed by AOP-RANTES in modulating the endocytic
trafficking of coreceptor molecules.
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